{"groups":[{"description":"Participants receive Cytarabine + Daunorubicin + Etoposide as their first course of chemotherapy. Subsequent therapy is risk-adapted.","id":"FG000","title":"Cytarabine+Daunorubicin+Etoposide"},{"description":"Participants receive Clofarabine + Cytarabine as their first course of chemotherapy. Subsequent therapy is risk-adapted.","id":"FG001","title":"Clofarabine+Cytarabine"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"17"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"11"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Received non-protocol therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"133"},{"groupId":"FG001","numSubjects":"129"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"98"},{"groupId":"FG001","numSubjects":"95"}],"comment":"\"For purposes of this report, a living subject \\*completes\\* the study three years after completion of therapy and the study is considered \\*complete\\* when all participants have died, been taken off study, or completed the study.\"","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"34"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Prior to starting the study, 62 participants were excluded for the following reasons: 29 participants were donors, 8 were determined to be ineligible (wrong diagnosis), 2 were MPAL (mixed AML) patients, and 23 were not randomized.","recruitmentDetails":"324 participants enrolled between August 2008 and March 2017."}